Anatara Lifesciences Bilan de santé

Santé financière contrôle des critères 6/6

Anatara Lifesciences possède un total de capitaux propres de A$1.4M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$1.7M et de A$306.8K.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$982.11k
Fonds propres	AU$1.36m
Total du passif	AU$306.85k
Total des actifs	AU$1.67m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ANR ( A$1.7M ) dépassent ses passifs à court terme ( A$304.2K ).

Passif à long terme: Les actifs à court terme de ANR ( A$1.7M ) dépassent ses passifs à long terme ( A$2.7K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ANR est sans dette.

Réduire la dette: ANR n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ANR dispose d'une piste de trésorerie suffisante pour 9 mois sur la base du dernier rapport flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Prévisions de trésorerie: ANR devrait disposer d'une marge de trésorerie suffisante pour 8 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

Anatara Lifesciences Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines